Showing 4071-4080 of 4164 results for "".
- Retina Specialist Brett Foxman, MD, Earns U.S. Patent for Scleral Depressorhttps://modernod.com/news/retina-specialist-brett-foxman-md-earns-u-s-patent-for-scleral-depressor/2476788/Brett Foxman, MD, Clinical Service Chief in Ophthalmology at Shore Medical Center in Somers Point, New Jersey, recently won a U.S. patent for his new version of the scleral depressor. Dr. Foxman said after performing thousands of eye surgeries using a tool that had stayed essentially uncha
- Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edemahttps://modernod.com/news/perspective-protocol-v-sheds-light-on-managing-mild-diabetic-macular-edema/2479555/When it comes to the treatment of diabetic macular edema (DME), ophthalmologists have overwhelming evidence to guide their decision-making—but only up to a point. DME consists of three clinical subcategories: center-involved DME (CI-DME) with visual acuity (VA) impairment, CI-DME with good
- Altris AI Algorithm for Detection of Retinal Conditions on OCT Scans Receives European CE Mark Approvalhttps://modernod.com/news/altris-ai-algorithm-for-detection-of-retinal-conditions-on-oct-scans-receives-european-ce-mark-approval/2479561/Altris AI announced that it has received the CE Mark approval for its Standard Functionality for retinal conditions detection on Optical Coherence Tomography (OCT) scans. Altris AI Standard Functionality is ready for preliminary screening of retinal diseases in clinical practice. Altris AI detect
- PolyActiva Completes Recruitment in Phase 1 Glaucoma Implant Safety Studyhttps://modernod.com/news/polyactiva-completes-recruitment-in-phase-1-glaucoma-implant-safety-study/2476759/PolyActiva has completed patient enrollment for its phase 1 clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma. Current glaucoma treatment requires eye drops to be administered daily, often multiple times each day
- EKF Quo-Test Supports Improved Medical Management of Diabetic Retinopathy Patientshttps://modernod.com/news/ekf-quo-test-supports-improved-medical-management-of-diabetic-retinopathy-patients/2476736/EKF Diagnostics announced that its Quo-Test HbA1c analyzer is supporting improved medical management of patients with sight-threatening diabetic retinopathy (DR). The effectiveness of this point-of-care HbA1c testing application for rapid assessment of glycaemic control in eye clinic patients has
- Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Deliveryhttps://modernod.com/news/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery/2476682/Alnylam Pharmaceuticals announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical
- Alcon Showcases News Contact Lens Innovations and the iLUX System at the 2019 Optometry’s Meetinghttps://modernod.com/news/alcon-showcases-news-contact-lens-innovations-and-the-ilux-system-at-the-2019-optometrys-meeting/2476673/Alcon will launch Dailies Colors contact lenses at the 2019 Optometry’s Meeting, as well as give attendees a preview of PRECISION1 contact lenses coming soon to the US. These innovations, together with updates on the iLUX MGD Treatment System, new clinical data and practice insights, will be feat
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Millionhttps://modernod.com/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million/2476641/Biogen announced that it has completed its acquisition of gene therapy company Nightstar Therapeutics, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical ass
- Phase 1/2 Study Evaluating THR-317 for DME Meets Primary Safety Endpointhttps://modernod.com/news/data-from-phase-1-2-clinical-study-evaluating-thr-317-anti-plgf-for-dme-presented-at-2019-floretina-meeting/2476638/Oxurion NV announced that clinical-stage data from a phase 1/2 study evaluating its anti-placental growth factor candidate THR-317 for the treatment of diabetic macular edema (DME) were presented at the FLORetina 2019 meeting in Florence, Italy. THR-317 (anti-PlGF) is a recombinant humanized mono